title: Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
abstract: In a study comparing the safety and immunogenicity of a recombinant DNA yeast-derived hepatitis B vaccine with that of a plasma-derived vaccine in young female adults, 50 subjects were vaccinated with the former and 29 with the latter vaccine according to a 0, 1, and 6 month vaccination schedule. Results indicated that the yeast-derived vaccine was safe and highly immunogenic. Two months after the second vaccine dose, 86% of subjects seroconverted, a rate which increased to 100%, 30 days after the booster dose. Moreover, anti-HBs geometric mean titres increased progressively after the first two doses and rose markedly to 1098 IU/l after the booster dose. Although similar rates of seroconversion were obtained with both vaccines, the anti-HBs GMT of the plasma-derived vaccine was higher (P less than 0.05) than that elicited by the yeast-derived vaccine.
authors.affiliation: Institute of Hygiene, University of Genoa, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Crovari
authors.forename: P C
authors.initials: PC
authors.lastname: Crovari
authors.forename: R C
authors.initials: RC
authors.lastname: Petrilli
authors.forename: G C
authors.initials: GC
authors.lastname: Icardi
authors.forename: P
authors.initials: P
authors.lastname: Bonanni
mesh_terms: D000328:Adult; D000941:Antigens / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant / Q000276:immunology; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006801:Humans; D011897:Random Allocation; D012441:Saccharomyces cerevisiae / Q000235:genetics; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000941:Antigens; D004274:DNA, Recombinant; D006510:Hepatitis B Antibodies; D014614:Vaccines, Synthetic